Resistance-repellent retroviral protease inhibitors

Details Resistance-repellent retroviral protease inhibitors Resistance-repellent retroviral protease inhibitors

2005-03-11

2010-10-05

Havlin, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S414000

Reexamination Certificate

active

07807845

ABSTRACT:
Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

REFERENCES:
patent: 5475027 (1995-12-01), Talley et al.
patent: 5502060 (1996-03-01), Thompson et al.
patent: 5703076 (1997-12-01), Talley et al.
patent: 5728718 (1998-03-01), Randad et al.
patent: 6319946 (2001-11-01), Hale et al.
patent: 6649651 (2003-11-01), Wigerinck et al.
patent: 7087373 (2006-08-01), Xie et al.
patent: 7109230 (2006-09-01), Erickson et al.
patent: 7157495 (2007-01-01), Wang et al.
patent: 7199148 (2007-04-01), Tahri et al.
patent: 7285566 (2007-10-01), Erickson et al.
patent: 2004/0132791 (2004-07-01), Surleraux et al.
patent: 2005/0107342 (2005-05-01), Erickson et al.
patent: 2005/0209301 (2005-09-01), Eissenstat et al.
patent: 2005/0261364 (2005-11-01), Wang et al.
patent: 2005/0267074 (2005-12-01), Eissenstat et al.
patent: 2006/0258627 (2006-11-01), Eissenstat et al.
patent: 2006/0293286 (2006-12-01), Erickson et al.
patent: 2007/0082883 (2007-04-01), Ghosh et al.
patent: WO 94/04492 (1994-03-01), None
patent: WO 95/06030 (1995-03-01), None
patent: WO 96/28463 (1996-03-01), None
patent: WO 96/28418 (1996-09-01), None
patent: WO 99/67254 (1999-06-01), None
patent: WO 99/67417 (1999-06-01), None
patent: WO 99/65870 (1999-12-01), None
patent: WO 00/76961 (2000-12-01), None
patent: WO 01/25240 (2001-04-01), None
patent: WO 2004/016619 (2004-02-01), None
Bundgaard, Drugs of the Future, 1991, 16(5), 443-458.
Byrn et al., Pharm. Res., v. 12, n. 7, p. 945-954, 1995.
Polymorphism in Pharmaceutical Solids, vol. 95, 1999, Taylor & Francis, Harry G. Brittain (Ed.), 427 pp. Up to p. 219 provided.
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages. TOC and pp. 243-244.
Lu et al., Bioorg Med Chem Lett 13 (2003) 1821-24).
Kirkiacharian et al., II Farmaco 57 (2002) 703-08.
Ghosh, A.K. Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-(Hydroxyethylamino) sulfonamide Isostere. Feb. 1998, vol. 8, No. 6, pp. 687-690, especially p. 689.
Arun K. Ghosh et al., Potent HIV Protease Inhibitors Incorporating . . . , Bioorganic & Medicinal Chemistry Letters, (1998), pp. 687-690, vol. 8.
Arun K. Ghosh et al., Structure Based Design : Novel Spirocyclic . . . , Bioorganic & Medicinal Chemistry Letters, (1998), pp. 979-982, vol. 8.
Arun K. Ghosh et al., Structure-Based Design of Non-Peptide HIV Protease . . . , IL FARMACO, (2001), pp. 29-32, vol. 56(1/2).
Kazuhisa Yoshimura et al., A Potent Human Immunodeficiency Virus Type 1 . . . , Journal of Virology, (2002), pp. 1349-1358, vol. 76(3).
Final Office Action issued on Sep. 17, 2008 for U.S. Appl. No. 11/490,555.

Affiliated with

Also associated with

Rating

Resistance-repellent retroviral protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Resistance-repellent retroviral protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Resistance-repellent retroviral protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4201182